title: Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2.
abstract: BACKGROUND
  Pancreatic cancer has significant morbidity and mortality worldwide. Good prognosis relies on an early diagnosis. The purpose of this study was to develop techniques for identifying cancer biomarkers in the serum of patients with pancreatic cancer.
  
  
  METHODS
  Serum samples from five individuals with pancreatic cancer and five individuals without cancer were compared. Highly abundant serum proteins were depleted by immuno-affinity column. Differential protein analysis was performed using 2-dimensional differential in-gel electrophoresis (2D-DIGE).
  
  
  RESULTS
  Among these protein spots, we found that 16 protein spots were differently expressed between the two mixtures; 8 of these were up-regulated and 8 were down-regulated in cancer. Mass spectrometry and database searching allowed the identification of the proteins corresponding to the gel spots. Up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2, which have not previously been implicated in pancreatic cancer, were observed. In an independent series of serum samples from 16 patients with pancreatic cancer and 16 non-cancer-bearing controls, increased levels of mannose-binding lectin 2 and myosin light chain kinase 2 were confirmed by western blot.
  
  
  CONCLUSIONS
  These results suggest that affinity column enrichment and DIGE can be used to identify proteins differentially expressed in serum from pancreatic cancer patients. These two proteins 'mannose-binding lectin 2 and myosin light chain kinase 2' might be potential biomarkers for the diagnosis of the pancreatic cancer.
authors.affiliation: Pancreatic Cancer Group, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Yefei
authors.initials: Y
authors.lastname: Rong
authors.forename: Dayong
authors.initials: D
authors.lastname: Jin
authors.forename: Chenrui
authors.initials: C
authors.lastname: Hou
authors.forename: Jianwen
authors.initials: J
authors.lastname: Hu
authors.forename: Wenchuan
authors.initials: W
authors.lastname: Wu
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Ni
authors.forename: Dansong
authors.initials: D
authors.lastname: Wang
authors.forename: Wenhui
authors.initials: W
authors.lastname: Lou
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D016022:Case-Control Studies; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D037601:Mannose-Binding Lectin / Q000097:blood*; D008875:Middle Aged; D009219:Myosin-Light-Chain Kinase / Q000097:blood*; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D040901:Proteomics; D053719:Tandem Mass Spectrometry; D015854:Up-Regulation / Q000502:physiology*
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; C445619:MBL2 protein, human; D037601:Mannose-Binding Lectin; D009219:Myosin-Light-Chain Kinase; C524358:cardiac myosin light chain kinase, human